Virapinib is an antiviral drug which is the first drug developed that acts by inhibiting viral entry into cells via macropinocytosis. While it is only in early developmental stages, initial testing showed broad spectrum antiviral activity against a range of viruses including SARS-CoV-2, Monkeypox virus, Ebolavirus and tick-borne encephalitis virus.[1]

Virapinib
Identifiers
  • [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]-[4-(4-methylpiperidin-1-yl)phenyl]methanone
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC26H36N6O
Molar mass448.615 g·mol−1
3D model (JSmol)
  • CC1CCN(CC1)C2=CC=C(C=C2)C(=O)N3CCC(C3)C4=NC5=C(CCN(C5)C)C(=N4)NC
  • InChI=1S/C26H36N6O/c1-18-8-13-31(14-9-18)21-6-4-19(5-7-21)26(33)32-15-10-20(16-32)24-28-23-17-30(3)12-11-22(23)25(27-2)29-24/h4-7,18,20H,8-17H2,1-3H3,(H,27,28,29)
  • Key:LUAVWTOZVHIDSI-UHFFFAOYSA-N

References

edit
  1. ^ Porebski B, Christ W, Corman A, Haraldsson M, Barz M, Lidemalm L, et al. (July 2024). "Discovery of a novel inhibitor of macropinocytosis with antiviral activity". Molecular Therapy. doi:10.1016/j.ymthe.2024.06.038. PMID 38956870.